Telos Capital Management Inc. Has $3.53 Million Stock Holdings in Abbott Laboratories (NYSE:ABT)

Telos Capital Management Inc. cut its position in Abbott Laboratories (NYSE:ABT) by 8.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 32,063 shares of the healthcare product maker’s stock after selling 2,966 shares during the period. Telos Capital Management Inc.’s holdings in Abbott Laboratories were worth $3,529,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Altshuler Shaham Ltd acquired a new stake in Abbott Laboratories in the fourth quarter worth $28,000. Cornerstone Planning Group LLC acquired a new stake in Abbott Laboratories in the second quarter worth $28,000. FWL Investment Management LLC acquired a new stake in shares of Abbott Laboratories during the fourth quarter worth $33,000. True Wealth Design LLC bought a new stake in Abbott Laboratories in the 4th quarter valued at $33,000. Finally, Quarry LP lifted its position in Abbott Laboratories by 132.9% in the 2nd quarter. Quarry LP now owns 333 shares of the healthcare product maker’s stock valued at $36,000 after acquiring an additional 190 shares in the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Evercore ISI boosted their price objective on shares of Abbott Laboratories from $120.00 to $125.00 and gave the company an “outperform” rating in a research report on Thursday, April 4th. Citigroup boosted their price target on shares of Abbott Laboratories from $126.00 to $128.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Royal Bank of Canada reissued an “outperform” rating and set a $128.00 price target on shares of Abbott Laboratories in a research report on Wednesday, February 14th. TheStreet raised shares of Abbott Laboratories from a “c+” rating to a “b-” rating in a research report on Thursday, December 21st. Finally, Raymond James boosted their price target on shares of Abbott Laboratories from $124.00 to $127.00 and gave the stock an “outperform” rating in a research report on Thursday, January 25th. Three investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat.com, Abbott Laboratories has a consensus rating of “Moderate Buy” and an average target price of $122.14.

Abbott Laboratories Stock Performance

Shares of Abbott Laboratories stock traded down $3.66 during trading on Wednesday, hitting $105.55. 8,510,960 shares of the stock were exchanged, compared to its average volume of 5,628,462. The stock has a market capitalization of $183.15 billion, a price-to-earnings ratio of 33.50, a price-to-earnings-growth ratio of 2.62 and a beta of 0.74. The company has a fifty day moving average price of $114.57 and a 200-day moving average price of $107.60. Abbott Laboratories has a 1-year low of $89.67 and a 1-year high of $121.64. The company has a current ratio of 1.64, a quick ratio of 1.16 and a debt-to-equity ratio of 0.35.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Wednesday, January 24th. The healthcare product maker reported $1.19 earnings per share for the quarter, hitting the consensus estimate of $1.19. Abbott Laboratories had a net margin of 14.27% and a return on equity of 20.65%. The company had revenue of $10.24 billion for the quarter, compared to analyst estimates of $10.19 billion. During the same period in the previous year, the business earned $1.03 EPS. Abbott Laboratories’s revenue for the quarter was up 1.5% compared to the same quarter last year. As a group, equities analysts predict that Abbott Laboratories will post 4.62 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, May 15th. Investors of record on Monday, April 15th will be paid a $0.55 dividend. The ex-dividend date is Friday, April 12th. This represents a $2.20 dividend on an annualized basis and a yield of 2.08%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 67.48%.

Insider Activity at Abbott Laboratories

In related news, EVP Andrea F. Wainer sold 42,500 shares of the company’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $112.50, for a total value of $4,781,250.00. Following the transaction, the executive vice president now owns 65,027 shares in the company, valued at approximately $7,315,537.50. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In other Abbott Laboratories news, EVP Andrea F. Wainer sold 12,500 shares of the stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $120.00, for a total transaction of $1,500,000.00. Following the transaction, the executive vice president now owns 78,704 shares in the company, valued at approximately $9,444,480. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Andrea F. Wainer sold 42,500 shares of the stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $112.50, for a total transaction of $4,781,250.00. Following the transaction, the executive vice president now owns 65,027 shares in the company, valued at approximately $7,315,537.50. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 56,435 shares of company stock worth $6,451,298. Insiders own 0.47% of the company’s stock.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.